Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed its Q1 2019 10-Q quarterly report on May 2, 2019 for the quarter ended Mar 31, 2019.
Teva Pharmaceutical Industries Ltd Q1 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4,295M, down 15% YoY from $5,055M, driven by COPAXONE competition and respiratory, U.S. generics declines
- Operating margin 3.1% vs 30.1% YoY; gross margin 43.2% vs 45.7%
- Best segment: Europe profit $403M, up 7%; worst: North America profit $498M, down 46%
- Cash and investments $2,040M vs $1,846M; operating cash flow $112M vs $1,496M
- Headwinds: FDA warning letter, valsartan recall, Japan pricing reductions, generic competition; sufficient liquidity expected for twelve months
Risk Factors
- No material changes identified, risk factors incorporated from the December 31, 2018 Form 10-K
- Regulatory risk: increased U.S. legal and regulatory action over opioid medication abuse
- Competitive risk: COPAXONE faces existing and potential additional generic competition
- Financial risk: substantial indebtedness may restrict financing and trigger further credit-rating downgrades
- Operational risk: manufacturing or quality-control problems could require costly remediation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teva Pharmaceutical Industries Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.